This site is intended for Healthcare Professionals only.

MHRA approves first drug via the new IRP in 30 days


Share post:

XGEVA is the first product to be authorised by the regulator through the new International Recognition Procedure (IRP).

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis.

It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP).

Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents.

The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors.

The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

“NHS patients should have access to the newest, most effective medicines and treatments without delay,” said Health Minister Andrew Stephenson.

“This new international agreement allows treatments to be approved more quickly by drawing on expertise from partners across the world, reducing bureaucracy and sharing resources so patients can benefit as soon as possible.

“XGEVA being approved quicker than usual is a testament to this innovative approach,” she added.

The European Medicines Agency (EMA) initially evaluated XGEVA, and on 25 January 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion.

The MHRA incorporated this assessment from the European regulator into its own review process.

“I’m very pleased to announce that we have granted the first approval through IRP in 30 days, demonstrating that this new process for bringing new medicines to UK patients is well under way,” said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

She assured that “appropriate regulatory standards” for the approval of this medicine have been met.

Denosumab, the active component in XGEVA, is a protein designed to decelerate bone destruction caused by the spread of cancer to the bone (bone metastasis) or by giant cell tumour of bone.

The IRP was launched in January this year, allowing the MHRA to accelerate the assessment of new medicines by taking into account the expertise and decision-making of trusted regulatory partners.

However, the MHRA retains ultimate authority to accept or reject applications submitted under the IRP.





Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Europe Sees Surge in Generic Medicines Withdrawals; UK Faces Doubling of Drug Shortages

Generic medicines for cancer and mental health on the Union List of Critical Medicines are disappearing, study reveals...

NHS to support newly-trained pharmacists with new £1.5 million investment

The new initiative is set to create highly-skilled placement opportunities in community pharmacies, GP surgeries, and care homes...

Professor Mahendra Patel joins UK Pharmacy Professional Leadership Advisory Board

The nine independent expert members of the UK Pharmacy Professional Leadership Advisory Board announced   Professor Mahendra Patel OBE,...

Silent suffering: 12k NHS staff reluctant to share mental health and well-being struggles

Latest UNISON survey underscores mental health absence affecting over 30 per cent of NHS staff including paramedics, and...